BeOne sells Imdelltra royalties for $885m upfront

BeOne Medicines announced a royalty purchase agreement with Royalty Pharma, involving an upfront payment of $885 million. The deal grants Royalty Pharma rights to tiered mid-single-digit royalty payments from Imdelltra ex-China net revenue.

An additional put option for up to $65 million exists until August 2026. BeOne retains rights to royalty payments above $1.5 billion.